-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] Recently, Huadong Medicine released a semi-annual performance report, and it is expected to achieve double growth in revenue and net profit, of which the operating income is 18.
198 billion yuan, a year-on-year increase of 5.
93%; the net profit is 1.
34 billion yuan, a year-on-year increase of 3.
09% %
.
According to the data, Huadong Pharmaceutical’s business covers the entire pharmaceutical industry chain, and is dominated by the pharmaceutical industry.
At the same time, it expands pharmaceutical business, medical beauty industry and industrial microbiology business.
It has developed into a large-scale comprehensive pharmaceutical listed company integrating pharmaceutical research and development, production and distribution.
.
In the pharmaceutical industry sector, the company continued to increase research and development.
In the first half of the year, the cumulative investment in research and development exceeded 500 million yuan, a year-on-year increase of 34%
.
Up to now, the company has a total of 86 pharmaceutical research projects, including 43 innovative drugs and biological drug projects; in addition, canagliflozin tablets, liraglutide injection, and sorafenib tosylate tablets are three major The pound products are expected to be approved before the end of the year, and they will enter the market of 100 billion yuan
.
Among them, canagliflozin is an SGLT2 inhibitor, which is mainly used to treat diabetes, but the mechanism of action of these drugs is different from that of traditional hypoglycemic drugs, mainly by inhibiting the activity of SGLT-2 to reduce the reabsorption of glucose by the kidneys , and increase urine sugar excretion, thereby lowering blood sugar
.
Canagliflozin is a Category B product in China's medical insurance catalogue, and the sales of this product in China's public medical institutions will exceed 200 million yuan in 2021
.
At present, the domestic product has formed a corporate structure of "1 original research + 4 domestic production".
Zhongmei Huadong submitted a generic listing application in January 2021.
The company is expected to be approved before the end of this year, which may be beneficial to the company in the field of 100 billion diabetes treatment.
further layout
.
Liraglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist with 97% sequence homology to human GLP-1.
It is mainly used to improve blood sugar control in adults with type 2 diabetes
.
The original researcher of the drug is Novo Nordisk, which entered the Chinese market in 2011 and entered the national medical insurance list through negotiation in 2017
.
Novo Nordisk’s financial report shows that in 2021, the global sales of liraglutide will be approximately DKK 15.
054 billion, of which the sales in China will be approximately DKK 1.
544 billion
.
Zhongmei Huadong submitted a marketing application to the State Food and Drug Administration in August 2021 and was accepted in September of that year
.
It is reported that Huadong Medicine's liraglutide (diabetes indication) is the first domestic liraglutide to submit a marketing application.
It has completed the drug registration review and is expected to be approved for marketing in China before the end of 2022.
Competitors such as Hanyu Pharmaceutical
.
Sorafenib Tosylate is a multi-kinase inhibitor, which can inhibit the growth of tumor cells.
It is clinically used for the treatment of inoperable advanced renal cell carcinoma and primary hepatocellular carcinoma with distant metastasis
.
The product was developed by Bayer and is a Category B product of the 2021 National Medical Insurance Catalogue.
In 2020, its sales in public medical institutions in China will exceed 1 billion yuan
.
From the perspective of the market structure, in addition to the original research, sorafenib tosylate tablets of 4 pharmaceutical companies have been approved for marketing, including Jiangxi Shanxiang Pharmaceutical, Chongqing Yaoyou Pharmaceutical, Yabao Bio and CSPC.
A competitive pattern of "1 original research + 4 domestic production" has been formed
.
Zhongmei Huadong submitted a generic application for sorafenib tosylate tablets in 2021, and the company expects to receive approval before the end of this year
.
In addition, the sorafenib tosylate tablet of Kelun Pharmaceutical is applying for listing, and there are also several pharmaceutical companies' generic drug production applications in the review and approval team
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
198 billion yuan, a year-on-year increase of 5.
93%; the net profit is 1.
34 billion yuan, a year-on-year increase of 3.
09% %
.
According to the data, Huadong Pharmaceutical’s business covers the entire pharmaceutical industry chain, and is dominated by the pharmaceutical industry.
At the same time, it expands pharmaceutical business, medical beauty industry and industrial microbiology business.
It has developed into a large-scale comprehensive pharmaceutical listed company integrating pharmaceutical research and development, production and distribution.
.
In the pharmaceutical industry sector, the company continued to increase research and development.
In the first half of the year, the cumulative investment in research and development exceeded 500 million yuan, a year-on-year increase of 34%
.
Up to now, the company has a total of 86 pharmaceutical research projects, including 43 innovative drugs and biological drug projects; in addition, canagliflozin tablets, liraglutide injection, and sorafenib tosylate tablets are three major The pound products are expected to be approved before the end of the year, and they will enter the market of 100 billion yuan
.
Among them, canagliflozin is an SGLT2 inhibitor, which is mainly used to treat diabetes, but the mechanism of action of these drugs is different from that of traditional hypoglycemic drugs, mainly by inhibiting the activity of SGLT-2 to reduce the reabsorption of glucose by the kidneys , and increase urine sugar excretion, thereby lowering blood sugar
.
Canagliflozin is a Category B product in China's medical insurance catalogue, and the sales of this product in China's public medical institutions will exceed 200 million yuan in 2021
.
At present, the domestic product has formed a corporate structure of "1 original research + 4 domestic production".
Zhongmei Huadong submitted a generic listing application in January 2021.
The company is expected to be approved before the end of this year, which may be beneficial to the company in the field of 100 billion diabetes treatment.
further layout
.
Liraglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist with 97% sequence homology to human GLP-1.
It is mainly used to improve blood sugar control in adults with type 2 diabetes
.
The original researcher of the drug is Novo Nordisk, which entered the Chinese market in 2011 and entered the national medical insurance list through negotiation in 2017
.
Novo Nordisk’s financial report shows that in 2021, the global sales of liraglutide will be approximately DKK 15.
054 billion, of which the sales in China will be approximately DKK 1.
544 billion
.
Zhongmei Huadong submitted a marketing application to the State Food and Drug Administration in August 2021 and was accepted in September of that year
.
It is reported that Huadong Medicine's liraglutide (diabetes indication) is the first domestic liraglutide to submit a marketing application.
It has completed the drug registration review and is expected to be approved for marketing in China before the end of 2022.
Competitors such as Hanyu Pharmaceutical
.
Sorafenib Tosylate is a multi-kinase inhibitor, which can inhibit the growth of tumor cells.
It is clinically used for the treatment of inoperable advanced renal cell carcinoma and primary hepatocellular carcinoma with distant metastasis
.
The product was developed by Bayer and is a Category B product of the 2021 National Medical Insurance Catalogue.
In 2020, its sales in public medical institutions in China will exceed 1 billion yuan
.
From the perspective of the market structure, in addition to the original research, sorafenib tosylate tablets of 4 pharmaceutical companies have been approved for marketing, including Jiangxi Shanxiang Pharmaceutical, Chongqing Yaoyou Pharmaceutical, Yabao Bio and CSPC.
A competitive pattern of "1 original research + 4 domestic production" has been formed
.
Zhongmei Huadong submitted a generic application for sorafenib tosylate tablets in 2021, and the company expects to receive approval before the end of this year
.
In addition, the sorafenib tosylate tablet of Kelun Pharmaceutical is applying for listing, and there are also several pharmaceutical companies' generic drug production applications in the review and approval team
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
